



ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2020 #14

April 17, 2020

INSIDE:

ABC Recognizes the 23 rd Annual Awards of Excellence Winners.....	2
Upcoming ABC Webinars – Don't Miss Out!.....	4
RESEARCH IN BRIEF.....	5
INFECTIOUS DISEASE UPDATES.....	5
ADRP Webinar: COVID-19 Pandemic Forum - Retention of New & Lapsed Donors During and After Pandemic.....	7
ABC Releases Thank You Video for Donors.....	7
Presentations Available from 2020 ABC Annual Meeting.....	7
REGULATORY NEWS.....	8
PEOPLE.....	8
BRIEFLY NOTED.....	8
GLOBAL NEWS.....	8
COMPANY NEWS.....	9
CALENDAR.....	9
POSITIONS.....	10

Administration Asks Those Recovered from COVID-19 to Be CCP Donors

This week, the Administration and federal agencies encouraged individuals across the country who have recovered from the coronavirus to become COVID-19 convalescent plasma (CCP) donors. On Wednesday, April 15th during a press briefing by the Administration's Coronavirus Task Force, both President Trump and Vice President Pence [discussed](#) the potential of CCP as a therapy to help critically-ill COVID-19 patients as they battle the disease that has now resulted in more than 632,000 confirmed cases and close to 27,000 confirmed deaths as of April 16th. “[S]omething which is incredible, keeps the virus from multiplying — a mechanism that keeps the virus from multiplying, immune therapies [sic] that prevent the immune system from overreaching to the virus and convalescent plasma treatments that use antibodies from the blood of recovered patients,” said President Trump. “[A]nd we have a lot of patients who recover and they're so happy to have recovered that the first thing they do is say ‘we want to give our blood’ and they do that. It's incredible. We have thousands of people that are doing that. They recover, they feel they have an obligation cause they've gotten such great care and a lot of them didn't think they were going to make it.” Vice President Pence added that “we wanted to announce today that the [U.S. Food and Drug Administration] FDA recently announced efforts to facilitate the development and access to convalescent plasma...People who have recovered from the coronavirus have antibodies in your bloodstream that can attack the virus...And we want to urge every American who has recovered from the coronavirus for at least two and preferably four weeks to contact your local blood or plasma donation center and arrange to donate. It's one more way that the American people can do their part and step forward. And thousands have already done so. And we know that tens of thousands will join them.”

The FDA also issued a [statement](#) on April 16th from Commissioner Stephen Hahn, MD that continued to urge recovered individuals to become CCP donors and announced the development of a [landing page](#) on the agency's website dedicated to CCP to “guide recovered COVID-19 patients to local blood or plasma collection centers to discuss their eligibility and potentially schedule an appointment to donate. The webpage also provides information for those interested in participating in the expanded access protocol, conducting clinical trials, or submitting eIND applications.” The landing page also includes links to the websites of the blood community including America's Blood Centers (ABC), AABB, American Red Cross, Armed Services Blood Program, and Blood Centers of America. During a recent [interview](#) on the Fox News Channel, the Commissioner stated, “we really encourage those Americans that had [COVID-19] to donate plasma and they can do that either through their local blood bank or the American Red Cross.”

(continued on page 2)



Administration Encourages CCP Donations (continued from page 1)

FDA Updates CCP Guidance. The agency also made a few minor changes on April 13th to the guidance entitled “[Investigational COVID-19 Convalescent Plasma Guidance for Industry](#)”. These included:

- (page 5), paragraph C, line 7: - added “if available” after mention of neutralizing antibodies;
- (page 6), last bullet at the bottom of page - added “when measurement of neutralizing antibody titers is available” to the beginning of that statement; and
- (page 7), revised bullet near the top of page from - “note: If neutralizing antibody titers cannot be obtained in advance,” to now state, “When measurement of neutralizing antibody titers is not available.”

Blood Community CCP Efforts Receive Support from Broad Coalition of Partners. Close to 20 organizations have agreed to support the blood community’s efforts in raising awareness throughout the country for individuals that have recovered from COVID-19 to donate CCP as a potential therapy treatment for critically ill COVID-19 patients. This group of stakeholders represents various sectors within healthcare, including national physician organizations, advanced practice nursing, medical devices, pharmacy, and patient advocacy organizations. A full list of supporters is available on the “[Supporters](#)” webpage of www.CovidPlasma.org launched by AABB last week “as an educational resource to inform the public, blood collectors, and clinicians about CCP.”

Additional resources, news, and updates regarding CCP and COVID-19 are also available on the ABC member site [COVID-19 Resource Hub](#) including recordings and slides from the recent Scientific, Medical, Technical Forum, Human Resources Forum, and Executive Update webinars.

(Sources: FDA [Statement](#), 4/16/20; Administration Task Force on Coronavirus [Briefing](#), 4/15/20; FDA CCP [Guidance](#), 4/13/20) 💧

ABC Recognizes the 23rd Annual Awards of Excellence Winners

America’s Blood Centers [honored](#) the recipients of the 23rd Annual *Awards of Excellence*, during the ABC Annual Meeting on March 10th. These awards allow ABC to recognize individuals and organizations that have made outstanding contributions in promoting blood donation and improving transfusion medicine.



William Coenen President’s Award. Jeanne Dariotis, a past president of ABC, and formerly the senior vice president of Laboratories and Reference Services at OneBlood, was recognized for her commitment in providing service to both the blood community and ABC members throughout her blood banking career. Ms. Dariotis was a fixture on several ABC Committees and served as the Board Chair of Group Services for America’s Blood Centers (GSABC). Her expertise and leadership helped the organization navigate the ever-evolving healthcare landscape.

Ruth Sylvester, ABC’s Director of Regulatory, was also honored with the President’s Award for her service to member blood centers over her 15-year career at ABC. She has been a career blood banker with more than 30 years of experience in both clinical laboratories and blood banks including military service as the director of the Armed Services Blood Program. Her expertise and influence have been a key component of ABC’s Scientific, Medical, and Technical team in addition to her contributions to leading ABC’s regulatory and disaster preparedness and response efforts. Ms. Sylvester has announced that she will retire during the current fiscal year.

(continued on page 3)



Awards of Excellence Recipients Honored (continued from page 2)

Thomas F. Zuck Lifetime Achievement Award. Gilles Delage, MD, MSc, vice president of Medical Affairs and Innovation, Microbiology at Hema-Quebec was this year's recipient of the Thomas F. Zuck Lifetime Achievement Award, which honors an individual for lifetime achievement in the application of clinical/medical and scientific research to improve methods of blood collection and the safety/efficacy of blood products provided to patients. Dr. Delage has been recognized for many noteworthy achievements in the fields of microbiology and infectiology applied to transfusion medicine in Canada and internationally. He was the first microbiologist in Canada to specialize in blood-borne diseases and has accomplished a great deal in terms of advocating risk management in public health – a priority he adopted during the course of his impressive career. He has been an integral part of ABC's SMT Committee and a resource to the members of ABC during his career and an advocate for transfusion safety and risk management in transfusion medicine.



Larry Frederick Award. Arjun Prasad Mainali nominated by New York Blood Center received the Larry Frederick Award, which honors an individual for his or her community leadership in raising awareness of the need for blood donations. He has been encouraging blood donation since 1987 and is a passionate sponsor of blood drives having donated blood in 17 countries on six continents. The blood center can count on Mr. Mainali to be an active blood donation counselor by dedicating most of his time in promoting and educating individuals about the importance of the ongoing need for blood donation. He also founded Blood Donors Association Nepal, Blood Donors of America, International Nepalese Blood Donors, and World Blood Donor Arjun Mainali Inc.

Corporation of the Year Award. The Arizona Diamondbacks, nominated by Vitalant, was honored with the Corporation of the Year Award, which is given to a business that demonstrates exceptional commitment to the volunteer blood community and to raising awareness of the need for blood donations. Since the late 1990's, Vitalant has received extraordinary support from the Diamondbacks organization who continues to prioritize blood donation within the community. From hosting blood drives to encouraging youth to remember the importance of blood donation, the support from the Diamondbacks organization starts with Derrick Hall, team president and chief executive officer, who has served on Vitalant's Community Leadership Council and promoted ongoing partnerships between his community relation's team and Vitalant.



ABC Outstanding Public Relations Campaign. The Mississippi Valley Regional Blood Center Marketing Department received the ABC Outstanding Public Relations Campaign Award for their "Change the World" campaign, which engaged audiences through a mission-driven initiative that told the story of how individuals can help make a difference in the world with the blood center. It also featured an employee engagement component with the team sharing content on how they were changing the world. The marketing team reached their three-year strategic goals in less than two year as social media followers increased by 30 percent, website visitors by 43 percent; and webpage views by 45 percent.

(continued on page 4)



Awards of Excellence Recipients Honored (continued from page 3)

ABC Outstanding Blood Drive of the Year Awards. Bradley County and Cleveland, Tenn. First Responders nominated by Blood Assurance was a recipient of the Outstanding Blood Drive of the Year. The Emergency Services of Bradley County and Cleveland, Tenn. held a friendly blood drive competition to honor first responders who served on 9/11. In total, 330 units were collected of which 62 donors were first time donors. Department participation was higher than their standard drives. The first-place winners, Bradley Co. EMS had a 77 percent participation while the Cleveland Fire Department had a 67 percent participation rate for the drive that resulted in the collection of 330 units and 62 first-time donors.



The Tyler Wilcox “Guns ‘n Hoses” blood drive, nominated by Vitalant, was also honored with an Outstanding Blood Drive of the Year Award. The drive, in memory of Tyler Wilcox who passed away in 2005 following a battle with osteosarcoma, has become a local blood drive competition between law enforcement and fire fighters and is a fixture within the community. The past year’s drive resulted in a new high mark of 420 units collected from 65 first-time donors.

[Photos](#) from the Annual *Awards of Excellence* Ceremony are available on ABC’s Flickr [page](#). ♦

Upcoming ABC Webinars – Don’t Miss Out!

- **ABC SMT Journal Club Webinar** – May 4th from 3 – 4:30 p.m. (EDT). More information coming soon.
- **ABC QA Education Webinar: FDA and the 356h Application Process** – Postponed (originally scheduled for May 19th). More information coming soon.

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2020 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the healthcare system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America’s Blood Centers

Chief Executive Officer: Kate Fry
 Chief Medical Officer: Rita Reik
 Editor: Mack Benton
 Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: \$390

Send subscription queries to memberservices@americasblood.org
 America’s Blood Centers
 1717 K St. NW, Suite 900, Washington, DC 20006
 Phone: (202) 393-5725
 Send news tips to newsletter@americasblood.org.

RESEARCH IN BRIEF

Effectiveness of Convalescent Plasma for Ten COVID-19 Patients. A pilot study published in the *Proceedings of the National Academy of Sciences of the United States of America (PNAS)* examined the efficacy of COVID-19 Convalescent Plasma (CCP) treatments in severe COVID-19 patients at three hospitals. Patient enrollment criteria included adults with respiratory distress, oxygen saturation level less than 93 percent, and partial pressure of oxygen (PaO₂)/oxygen concentration (FiO₂) ≤ 300 mmHg. “Ten donors who recovered from COVID-19 were recruited” and recovery criteria included: normal body temperature for more than three days, resolution of respiratory symptoms, and two negative results of sputum SARS-CoV-2 by reverse transcriptase polymerase chain reaction (RT-PCR) assay. “All patients were admitted to the intensive care unit and received antiviral therapy.” The donor’s plasma was collected by apheresis three weeks after the onset of illness and underwent pathogen reduction. One dose of 200 mL of CCP with neutralization activity of >1:640 was transfused. The patients’ symptoms, especially fever, cough, shortness of breath, and chest pain, disappeared or improved within three days. “Two patients were weaned from mechanical ventilation and one discontinued high-flow nasal cannula. Lymphocytopenia improved in seven patients (median: 0.65×10^9 vs. 0.76×10^9 per L). There was a decrease in C-reactive protein (median: 55.98 vs. 18.13 mg/L), alanine aminotransferase (median: 42.00 vs. 34.30 U/L), and aspartate aminotransferase (median: 38.10 vs. 30.30 U/L). The increase of SaO₂ (median: 93.00 vs. 96.00 percent) “could indicate recovering lung function.” Researchers found that the “neutralizing antibody titers of five patients increased.” SARS CoV-2 RNA, assayed by RT-PCR, was positive in seven patients before CCP transfusion and undetectable in all by day six. A historic control group was formed by random selection of ten patients being treated in the same hospitals for COVID-19. Clinical outcomes of these two groups were different as the CCP group had three patients discharged and seven were ready for discharge compared to the controls with three deaths, six cases stable, and none discharged. The authors concluded that this pilot study on CCP therapy “show[ed] a potential therapeutic effect and low risk in the treatment of severe COVID-19 patients.”

Citation: Duan, K., Li, B., Li, C., *et al.* Effectiveness of Convalescent Plasma Therapy in Severe COVID-19 Patients. *PNAS*. 2020. Doi. [10.1073/pnas.2004168117](https://doi.org/10.1073/pnas.2004168117).

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧

INFECTIOUS DISEASE UPDATES

EBOLA


Three new cases of Ebola have been confirmed in the Democratic Republic of Congo (DRC). This comes in the wake of an announcement last month that the last individual with a confirmed case of Ebola had been released from a treatment center on March 3rd. “The World Health Organization (WHO) has worked side by side with health responders from the DRC for over 18 months and our teams are right now supporting the investigation into this latest case,” said Dr Matshidiso Moeti, WHO Regional Director for Africa in agency news [release](#). “Although the ongoing COVID-19 pandemic adds challenges, we will continue this joint effort until we can declare the end of this Ebola outbreak together.” The outbreak has been ongoing for more than a year and a half with over 2,200 individuals having died during the outbreak. Throughout the outbreak, the Centers for Disease Control and Prevention (CDC) and the WHO did not classify the affected areas as having “widespread transmission of Ebola virus,” which would trigger donor interventions in the U.S. The U.S. Food and Drug Administration (FDA) [guidance](#) requires that “in the event that one or more countries is classified by CDC as having widespread transmission of Ebola virus, your donor history questionnaire (DHQ), including your full-length and abbreviated DHQ, and accompanying materials, must incorporate elements to assess prospective donors for symptoms of recent or current illness with Ebola virus

(continued on page 6)

INFECTIOUS DISEASE UPDATES (continued from page 5)

infection or disease, and travel to, or residence in, an area endemic for Ebola virus in accordance with 21 CFR 630.10(e)(2).” As of April 14th, there were 3,323 confirmed cases with 2,277 confirmed deaths.

Confirmed and probable Ebola virus disease cases by week of illness onset, data as of April 14th*




*Excludes n=130/3458 cases for whom onset dates not reported. Data in recent weeks are subject to delays in case confirmation and reporting, as well as ongoing data cleaning. ‘Non-active zones’ indicate health zones that have not reported new cases in the last 42 days.

(Sources: WHO News [Release](#) 4/10/20, [Ebola virus disease – Democratic Republic of the Congo](#), 4/16/20)



RESEARCH BRIEFS

America’s Blood Centers welcomes contributions or briefs from guest authors for scientific/medical peer-reviewed published papers. The views/comments expressed in submitted articles from external parties are those of the author(s) and are not to be interpreted as the viewpoint of America’s Blood Centers. If you are interested in contributing a brief for potential publication please contact us [here](#).





America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

ADRP Webinar: COVID-19 Pandemic Forum - Retention of New & Lapsed Donors During and After Pandemic

[Register](#) today for the Wednesday, May 6th ADRP Webinar entitled “COVID-19 Pandemic Forum - Retention of New and Lapsed Donors During and After Pandemic.” This webinar will take place at 1 p.m. EDT and will feature a panel discussion of strategies to use for engaging and retaining blood donors that have responded to outreach efforts. The panelists include Theresa Pina, vice president of Operations at Gulf Coast Regional Blood Center, Amanda Farrell, director of Donor Recruitment for ConnectLife, and Amanda Hess, director Donor and Public Relations for Mississippi Valley Regional Blood Center. ADRP subscribers may register for free and non-subscribers can participate for \$25.

(ADRP [Announcement](#), 4/16/20)

ABC Releases Thank You Video for Donors

To recognize the extraordinary response by blood donors across the country to ensure the availability of the nation's blood supply during the COVID-19 pandemic, ABC has created a [thank you video](#). It acknowledges donors and encourages them to make future appointments to meet the nation's ongoing blood needs. ABC commends the work of the blood community during this unprecedented time to keep the blood supply safe and ready for patients in need.

(Source: ABC [Video](#), 4/10/20)

Presentations Available from 2020 ABC Annual Meeting

ABC has uploaded [presentations](#) from the 2020 ABC Annual meeting to the member website. Access to the presentations is available to all member blood centers. Please note that only presentations for which speakers provided permission to share can be accessed. For any questions or issues, please contact [Member Services](#).

(Source: [MCN 20-041](#), 4/9/20) ♦

We Welcome Your Letters

The *ABC Newsletter* welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the *ABC Newsletter*. Letters are subject to editing for brevity and good taste and published after editorial review. Please send letters to the Editor at newsletter@americasblood.org or fax them to (202) 899-2621. Please include your correct title and organization as well as your phone number. The deadline for letters is Wednesday to make it into the next newsletter.



REGULATORY NEWS

The U.S. Food and Drug Administration's (FDA) Cellular and Gene Therapies Advisory Committee will meet on May 8th via teleconference according to a recent announcement. The meeting is open to the public and will take place from 1:00 - 4:55 p.m. EDT. The committee "will hear an overview and updates of research programs in the Tumor Vaccines and Biotechnology Branch (TVBB) and Cellular and Tissue Therapy Branch (CTTB), Division of Cellular and Gene Therapies (DCGT), Office of Tissues and Advanced Therapies (OTAT), Center for Biologics Evaluation and Research, FDA." A webcast of the meeting will be [available](#). Additional meeting materials and information will be available on the committee's [website](#). Individuals that would like to make verbal or written comments must notify the agency on or before May 1st.

(Source: FDA [Announcement](#), 4/16/20) 💧

PEOPLE



Marc Pearce, MBA has been named the new president and chief executive officer of The American Association of Tissue Banks (AATB) as of June 1st. "I am humbled at the opportunity to become the next President and CEO of AATB, a prestigious organization with a strong commitment to donor and patient, safety and care, especially during this critical time in the U.S. healthcare," said Mr. Pearce in the announcement. He currently serves as the vice president of Business Systems for Creative Testing Solutions, a role he has held since 2011, and previously held the role of chief marketing officer at AABB.

(Source AATB [Announcement](#), 4/13/20) 💧

BRIEFLY NOTED

AABB has announced an extension until Friday, May 15th for the call for abstracts to be presented at the 2020 AABB Annual Meeting in Baltimore, Md. from Oct. 3rd to 6th. AABB encourages individuals to [submit](#) abstracts online to share knowledge with colleagues by completing submissions on or prior to the aforementioned deadline. Acceptance notifications are expected to be distributed in July. A guide to assist with preparation and submission guidelines is available for [download](#). More information and submission instructions can be found [here](#).

(Source: AABB [Announcement](#)) 💧

GLOBAL NEWS

The Australian Department of Health's Therapeutic Goods Administration (TGA) has [approved](#) a recommendation by the Australian Red Cross Lifeblood, the country's national blood collection organization, to reduce the deferral period from 12-months to three for whole blood donors whose sexual activity is considered high risk. According to the agency, the submission and advice received from the Advisory Committee on Biologicals is the basis for the decision, which has been made following the risk analysis supplied by Lifeblood which demonstrates that "recipient safety remains within accepted risk tolerance parameters. Following the regulatory decision to accept the proposal to reduce the deferral period,

(continued on page 9)

GLOBAL NEWS (continued from page 8)

implementation of the change will involve consideration by the Commonwealth, State, and Territory governments that fund and indemnify Lifeblood's activities.” The deferral reduction applies to:

- for male donors: male-to-male sex;
- for female donors: sex with a man who has ever had sex with a man;
- for transgender donors: sexual contact with a male;
- sex work;
- sexual contact with a sex worker (male or female);
- overseas sexual contact with a resident of a HIV high prevalence country;
- sexual contact with an injecting drug user (current or past); and
- sexual contact with a partner known to be infected with a blood-borne virus (HIV, HBV, HCV or HTLV).

(Source: Australian TGA [Announcement](#), 4/15/20) ♦

COMPANY NEWS

Cerus Corp. [announced](#) that Central California Blood Center has become the first blood center in the U.S. to implement pathogen reduction technology for COVID-19 convalescent plasma (CCP) from recovered COVID-19 patients for use as a therapy to treat critically-ill COVID-19 patients. “We look forward to being able to safely collect, process and pathogen-reduce these plasma donations,” said Christopher Staub, president and chief executive officer of the Central California Blood Center in the announcement. “By following approved [U.S. Food and Drug Administration] FDA guidance, [Occupational Safety and Health Administration] OSHA safety standards and the very latest scientific evidence suggesting this could save lives, we’re looking to make rapid progress through approved research and specially FDA emergency-authorized use to fight against COVID-19.”

(Cerus [Announcement](#), 4/3/20) ♦

CALENDAR

***Note to subscribers:** Submissions for a free listing in this calendar (published in the last issue of each month) are welcome. Send information to newsletter@americasblood.org or by fax to (202) 899-2621. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)*

Canceled Meetings

April 23-24. **13th Annual FDA/AdvaMed Medical Devices and Diagnostics Statistical Issues Conference, Washington D.C.** More details available [here](#).

May 12-13. **AABB and Mayo Clinic Laboratories Transfuse 2020, Rochester, Minn.** More details available [here](#).

May 13-14. **IPFA/PEI 27th International Workshop on “Surveillance and Screening of Blood-Borne Pathogens, Porto, Portugal.** More details available [here](#).

(continued on page 10)

CALENDAR (continued from page 9)**2020**

April 27. **U.S. Department of Health and Human Services Tick-borne Disease Working Group Meeting (Teleconference)**. More details available [here](#).

May 8. **U.S. Food and Drug Administration (FDA) Cellular, Tissue and Gene Therapies Advisory Committee Meeting, Teleconference**. More details available [here](#).

July 21-23. **2020 ABC Medical Directors Workshop and Summer Summit, Cleveland, Ohio**. More details coming soon.

Aug. 28-29. **64th Annual California Blood Bank Society Annual Meeting, Santa Clara, Calif.** More details available [here](#).

Sept. 9. **10th Annual Symposium Red Cell Genotyping 2020: Visionary Solutions, Bethesda, Md.** More details available [here](#).

Sept. 10. **39th Annual Immunohematology and Blood Transfusion Symposium, Bethesda, Md.** More details available [here](#).

Sept. 23-25. **4th European Conference on Donor Health and Management, Hamburg, Germany.** More details available [here](#).

Oct. 3-6. **2020 AABB Annual Meeting, Baltimore, Md.** More information available [here](#).

Nov. 22-24. **2020 ADRP Conference, Phoenix, Ariz.** More details available [here](#). 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Director, Regulatory Affairs. America's Blood Centers (ABC), North America's largest network of community-based, independent blood programs, is seeking a Director, Regulatory Affairs. The position will be actively involved and accountable for the development, implementation, execution and advancement of the ABC regulatory agenda before federal agencies and other stakeholders. In addition, the position will assist in the facilitation of member education, evaluation and coalescing of member input in the development of industry positions, data collection from internal and external sources, and primary and secondary research. The position will report directly to the Senior Director, Federal Government Affairs, providing strategic guidance on regulatory affairs and public policy issues pertaining to the nation's blood supply. A bachelor's degree is required for the position, which is based in Washington, D.C. This individual should: have a thorough understanding of the federal regulatory processes and landscape, particularly with the FDA; have knowledge of and experience in health policy; blood industry knowledge preferably (but not required); be able to collect, analyze, and synthesize

information from varied sources; have strong critical thinking, analytical, and problem-solving skills; be self-motivated and goal oriented; have the ability to multitask and determine priorities; be able to network and collaborate effectively with colleagues and volunteers; have strong communication skills - verbal, written, and presentation; and be able to travel, sometimes at short notice. ABC offers a salary commensurate with experience as well as an excellent benefit package including medical, dental, LTD, and 401k contribution. We are a hybrid virtual office that promotes a flexible work environment. This is a full-time staff position including benefits and a stipend for internet and telephone services. ABC prohibits discrimination and provides equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws. The full job description is

(continued on page 11)

POSITIONS (continued from page 10)

available [here](#). Interested applicants should send a cover letter and resume to careers@americasblood.org.

Hematologist/Medical Director. OneBlood is expanding its clinical practice offerings in the areas of outpatient transfusion medicine, therapeutic apheresis & phlebotomy, pre-op anemia management, cell therapy, treatment of blood disorders. If you have a passion to join a team that is providing cutting-edge medical expertise in the areas of blood banking/transfusion medicine, hematology and outpatient clinical services, IRL, therapeutic apheresis, cellular therapy, research, consider joining our medical team as a regional Medical Director. This position includes a highly competitive salary, benefits package, including the option of free medical coverage,

retirement plan with company contribution PLUS a company match, company vehicle lease/allowance, paid holidays, etc. The position is based out of the Ft. Lauderdale, Florida area. Qualified candidates should possess minimum of 3 years' experience, M.D. or D.O. degree with board certification in Internal Medicine/Hematology and sub-specialty board certification in Blood Banking/Transfusion Medicine by a Board Registry recognized by the American Board of Medical Specialties. Appropriate state licenses will be required as needed. Candidates must meet the eligibility requirements to obtain appointments at hospitals served by OneBlood. For more detailed information, visit OneBlood's Careers page at www.oneblood.org. OneBlood, Inc., a proven leader in blood banking, is an Equal Opportunity Employer/Vet/Disability. ♦